Market closedADR
Grifols/$GRFS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Grifols
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Ticker
$GRFS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
23,000
Website
Grifols Metrics
BasicAdvanced
$6B
Market cap
30.30
P/E ratio
$0.25
EPS
0.70
Beta
-
Dividend rate
Price and volume
Market cap
$6B
Beta
0.7
52-week high
$12.15
52-week low
$5.30
Average daily volume
1.3M
Financial strength
Current ratio
2.26
Quick ratio
0.77
Long term debt to equity
110.521
Total debt to equity
123.24
Interest coverage (TTM)
1.61%
Management effectiveness
Return on assets (TTM)
2.87%
Return on equity (TTM)
2.71%
Valuation
Price to earnings (TTM)
30.304
Price to revenue (TTM)
0.699
Price to book
1.07
Price to tangible book (TTM)
-1.08
Price to free cash flow (TTM)
23.399
Growth
Revenue change (TTM)
7.21%
3-year revenue growth (CAGR)
11.57%
3-year earnings per share growth (CAGR)
-23.28%
What the Analysts think about Grifols
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Grifols stock.
Grifols Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Grifols Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Grifols News
AllArticlesVideos
Flat Footed Calls for Prompt Governance Overhaul at Grifols
Business Wire·2 weeks ago
Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga
Business Wire·3 weeks ago
Statement From Araoz y Rueda on Behalf of Certain Institutional Investors in Grifols
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Grifols stock?
Grifols (GRFS) has a market cap of $6B as of December 22, 2024.
What is the P/E ratio for Grifols stock?
The price to earnings (P/E) ratio for Grifols (GRFS) stock is 30.3 as of December 22, 2024.
Does Grifols stock pay dividends?
No, Grifols (GRFS) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next Grifols dividend payment date?
Grifols (GRFS) stock does not pay dividends to its shareholders.
What is the beta indicator for Grifols?
Grifols (GRFS) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.